Characterization of a novel PET radioligand for mitochondrial complex I in nonhuman primate [0.03%]
一种新的非人灵长类PET放射配体的表征用于线粒体复合物I
Yulong Xu,Yiming Xu,Frederick Andrew Bagdasarian et al.
Yulong Xu et al.
The role of mitochondrial complex I (MC-I) dysfunction is well-documented across a range of neurodegenerative disorders. Recently, a novel positron emission tomography (PET) radioligand, [18F]CNL02, has been synthesized to target MC-I. In t...
Preclinical evaluation of 68Ga-labeled folic acid conjugates for visualization of inflammatory foci [0.03%]
68镓标记叶酸偶联物可视化炎症病灶的临床前评估研究
Kristina A Petrosova,Aleksandr S Lunev,Marat G Rakhimov et al.
Kristina A Petrosova et al.
Introduction: Folate receptors (FR) have been considered a convenient target for different radiopharmaceuticals in recent years. Multifarious 68Ga-labeled folate conjugates have been proposed as promising agents for the P...
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy [0.03%]
阿尔法地图：绘制靶向α疗法放射性核素的全球生产分布图
Marianna Tosato,Chiara Favaretto,Janke Kleynhans et al.
Marianna Tosato et al.
Targeted Alpha Therapy has shown great promise in cancer treatment, sparking significant interest over recent decades. However, its broad adoption has been impeded by the scarcity of alpha-emitters and the complexities related to their use....
Solid phase extraction chromatography-based radiochemical isolation of cyclotron-produced 51Mn from enriched 54Fe targets [0.03%]
基于固相萃取色谱的回旋加速器产生的51Mn放射化学分离法及其富集54Fe靶的应用
Kendall E Barrett,Jason C Mixdorf,Johan Svedjehed et al.
Kendall E Barrett et al.
We report DGA extraction chromatography isolation of 51Mn from isotopically enriched 54Fe. The method has been studied in semi-automated and automated realizations. The former achieves a decay corrected radiochemical yield of 78 ± 1 % (n =...
PET imaging of the anticancer drug candidate [11C]trimebutine in a rat glioma model [0.03%]
放射性示踪剂[11C]特明布丁的动物脑瘤皮层模型中的正电子发射断层显影(PET)影像研究
Jia-Zhe Lin,Maria Kominia,Janine Doorduin et al.
Jia-Zhe Lin et al.
Purpose: Preclinical studies suggest that trimebutine could be a potential treatment for glioblastoma. The aim of this study was to investigate the distribution, kinetics and tumor accumulation of [11C]trimebutine. ...
Transmembrane protein 106B amyloid is a potential off-target molecule of tau PET tracers in the choroid plexus [0.03%]
tau PET示踪剂在脉络丛中的潜在脱靶分子为跨膜蛋白106B淀粉样物质
Yuka Yokoyama,Ryuichi Harada,Kaede Kudo et al.
Yuka Yokoyama et al.
Purpose: Tau positron emission tomography (PET) has become an essential tool for the clinical diagnosis of neurodegenerative diseases and the study of tau pathology in the brain. However, some tau tracers exhibit off-targ...
Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer [0.03%]
针对MUC16阳性高级别浆液性卵巢癌的预定点alpha疗法
Kyeara N Mack,David Bauer,Lukas M Carter et al.
Kyeara N Mack et al.
Background: Peritoneal metastasis with micrometastatic cell clusters is a common feature of advanced ovarian cancer. Targeted alpha therapy (TAT) is an attractive approach for treating micrometastatic diseases as alpha pa...
225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates [0.03%]
一种用于直接合成213Bi标记生物缀合物的225Ac/213Bi发生器
Stanislav V Ermolaev,Aleksandr N Vasiliev,Aino K Skasyrskaya et al.
Stanislav V Ermolaev et al.
Background: 213Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of 213Bi during a conventional synthesis of r...
NMB Innovators Series Professor Jon Dilworth: Shining a Light on the Chemistry of Metals Used in Biology, Medicine and Radiochemistry: With this series of editorials, NMB honors the scientists in the radiopharmaceutical sciences domain that have dedicated their career to our field and made substantial contributions [0.03%]
NMB创新者系列：Jon Dilworth教授：揭示用于生物学、医学和放射化学的金属元素的化学性质：通过本系列社论，NMB表彰了其职业生涯致力于放射性药物科学领域并为此做出重大贡献的科学家们。
Jonathan R Dilworth,Jason S Lewis,Sofia I Pascu
Jonathan R Dilworth
New prospects for 89Zr-immuno-PET in brain applications - Alpha-synucleinopathies [0.03%]
89Zr-免疫PET在脑应用中的新前景-α-突触核蛋白病
Thomas E Wuensche,Pedro M Pereira,Albert D Windhorst et al.
Thomas E Wuensche et al.
Background: Recently, 89Zr-immuno-PET imaging of therapeutic antibodies, actively transported over the blood-brain-barrier via transferrin-mediated transcytosis, was demonstrated using the chelator DFO*. In these studies,...